A point-of-care conduction device may provide accurate measurements of nerve amplitude potential and conduction velocity for the diagnosis of polyneuropathy in older patients.
Privigen is stabilized with proline, which has been shown to reduce IgG aggregation and dimer formation.
Long-term treatment with opioids is associated with more adverse outcomes in patients with polyneuropathy, including depression, overdose, and opioid dependence.
Polyneuropathy may increase the likelihood of patients receiving long-term opioid therapy.
Researchers identified 3 subgroups of patients with peripheral neuropathic pain, based on sensory signs and symptoms.
Diabetes, prediabetes, and obesity may be metabolic drivers of polyneuropathy.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force